FluNhance™

FluNhance™ is in development as a potential efficacy-enhancing additive to influenza vaccines through the addition of recombinant neuraminidase (rNA) to the vaccine formulation. Neuraminidase (NA) is another vaccine antigen target for influenza, however, there are no other licensed vaccines standardized with a known amount of NA content.

FluNhance™ has completed Phase II(b) challenge studies conducted by NIAID which demonstrated safety and reduction of virus shedding (virus spread) coupled with less severe and shorter duration of illness compared to the licensed vaccine alone.

FluNhance™ Advantages:

Efficacy enhancing additive for all influenza vaccines
Less severe and shorter duration of illness if infected with influenza
No preservatives (i.e. no thimerisol)
No egg proteins present
Pandemic influenza applications

References:

WHO workshop
Reviews summarizing clinical studies